TherapeuticsMD, Inc. (TXMD) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: 8.85
30Y Low8.8·High8.8
P/FCF
31.78
↑+135% vs avg
5yr avg: 13.55
30Y Low1.4·High13.5
P/B Ratio
↓
0.85
-2% vs avg
5yr avg: 0.87
30Y Low0.4·High81.6
ROE
↓
-7.7%
↑-108% vs avg
5yr avg: 93.0%
30Y Low-330%·High319%
Debt/EBITDA
N/A
—
5yr avg: 3.66
30Y Low0.2·High3.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TXMD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
TherapeuticsMD, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 31.8x P/FCF, 135% above the 5-year average of 13.5x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $23M | $10M | $23M | $50M | $143M | $334M | $596M | $857M | $1.2B | $1.1B | $1.8B |
| Enterprise Value | $25M | $12M | $27M | $21M | $276M | $502M | $641M | $769M | $1.1B | $1000M | $1.7B |
| P/E Ratio → | -10.58 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 13.21 | 5.63 | 18.04 | 0.72 | 55.69 | 5.14 | 12.01 | 53.25 | 73.99 | 58.45 | 89.15 |
| P/B Ratio | 0.85 | 0.36 | 0.80 | 1.44 | — | — | 64.79 | 8.79 | 9.56 | 8.87 | 28.48 |
| P/FCF | 31.78 | 13.55 | — | — | — | — | — | — | — | — | — |
| P/OCF | 31.78 | 13.55 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TXMD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.83 | 20.87 | 0.30 | 107.29 | 7.73 | 12.90 | 47.77 | 66.41 | 51.66 | 85.94 |
| EV / EBITDA | — | — | — | 8.85 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | 1.98 | — | — | — | — | — | — | — |
| EV / FCF | — | 16.44 | — | — | — | — | — | — | — | — | — |
TXMD Profitability
Margins and return-on-capital ratios measuring operating efficiency
TherapeuticsMD, Inc. earns an operating margin of -270.3%. Operating margins have compressed from 1.7% to -270.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -7.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 98.0% | 45.5% | 75.4% | 87.2% | 83.0% | 84.3% | 78.4% | 77.6% |
| Operating Margin | -270.3% | -270.3% | -654.6% | 1.7% | -3092.8% | -239.8% | -304.6% | -808.8% | -462.7% | -466.3% | -422.9% |
| Net Profit Margin | -123.9% | -123.9% | -789.4% | 160.1% | -6700.9% | -282.9% | -354.8% | -823.7% | -458.5% | -464.3% | -422.4% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.7% | -7.7% | -31.9% | 318.7% | — | — | -330.1% | -116.6% | -59.8% | -94.3% | -152.7% |
| ROA | -5.3% | -5.3% | -15.4% | 86.2% | -98.2% | -82.0% | -73.7% | -74.7% | -53.9% | -83.1% | -128.1% |
| ROIC | -11.4% | -11.4% | -32.9% | 4.0% | -143.3% | -238.6% | -360.3% | -1619.0% | -2099.5% | — | — |
| ROCE | -13.6% | -13.6% | -21.3% | 2.7% | -408.6% | -92.8% | -78.8% | -86.6% | -60.3% | -94.7% | -152.9% |
TXMD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $2M ($7M total debt minus $5M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.26 | 0.26 | 0.27 | 0.25 | — | — | 22.31 | 0.75 | — | — | — |
| Debt / EBITDA | — | — | — | 3.66 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.08 | 0.13 | -0.83 | — | — | 4.83 | -0.90 | -0.98 | -1.03 | -1.03 |
| Net Debt / EBITDA | — | — | — | -12.26 | — | — | — | — | — | — | — |
| Debt / FCF | — | 2.89 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -501.05 | -501.05 | — | — | -2.42 | -5.44 | -8.70 | -27.84 | — | — | — |
TXMD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.92x means TherapeuticsMD, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.18x to 1.92x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.92 | 1.92 | 1.72 | 1.18 | 0.47 | 2.17 | 3.93 | 4.55 | 10.48 | 9.30 | 6.63 |
| Quick Ratio | 1.92 | 1.92 | 1.72 | 1.18 | 0.44 | 2.03 | 3.71 | 4.47 | 10.36 | 9.23 | 6.56 |
| Cash Ratio | 0.98 | 0.98 | 0.63 | 0.81 | 0.26 | 1.36 | 3.03 | 3.93 | 9.54 | 8.78 | 6.07 |
| Asset Turnover | — | 0.05 | 0.03 | 0.77 | 0.02 | 0.36 | 0.19 | 0.08 | 0.12 | 0.14 | 0.27 |
| Inventory Turnover | 0.18 | — | — | — | 0.18 | 2.00 | 0.53 | 0.84 | 1.78 | 3.89 | 6.53 |
| Days Sales Outstanding | — | 738.29 | 866.24 | — | 5131.85 | 182.20 | 179.36 | 250.83 | 94.17 | 84.87 | 55.26 |
TXMD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
TherapeuticsMD, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 3.1% | 7.4% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 76.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 76.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $12M | $10M | $9M | $8M | $6M | $5M | $5M | $4M | $4M | $3M |
Peer Comparison
Compare TXMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TXMDYou | $23M | -10.6 | — | 31.8 | 100.0% | -270.3% | -7.7% | -11.4% | — |
 PGNY | $2B | 29.5 | 16.4 | 8.2 | 23.6% | 6.6% | 12.5% | 18.1% | 0.3 |
 DARE | $25M | -6.1 | — | 5.3 | -146110.2% | -239692.2% | — | — | — |
 ANIP | $2B | 25.3 | 9.0 | 9.6 | — | 12.6% | 16.2% | 11.2% | 1.6 |
 EVAX | $26M | -3.4 | — | — | 99.7% | -122.7% | -100.5% | -295.2% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 TEVA | $42B | 30.0 | 17.6 | 36.5 | 51.8% | 12.5% | 20.7% | 7.7% | 5.5 |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 MCK | $92B | 29.2 | 18.7 | 17.6 | 3.5% | 1.2% | — | 540.6% | 1.5 |
 CAH | $44B | 28.7 | 16.0 | 23.6 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See TXMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TXMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TXMD vs PGNY
Side-by-side business, growth, and profitability comparison vs Progyny, Inc..
Start ComparisonTXMD — Frequently Asked Questions
Quick answers to the most common questions about buying TXMD stock.
What is TherapeuticsMD, Inc.'s P/E ratio?
TherapeuticsMD, Inc.'s current P/E ratio is -10.6x. The historical average is 3.1x.
What is TherapeuticsMD, Inc.'s ROE?
TherapeuticsMD, Inc.'s return on equity (ROE) is -7.7%. The historical average is -29.5%.
Is TXMD stock overvalued?
Based on historical data, TherapeuticsMD, Inc. is trading at a P/E of -10.6x. Compare with industry peers and growth rates for a complete picture.
What are TherapeuticsMD, Inc.'s profit margins?
TherapeuticsMD, Inc. has 100.0% gross margin and -270.3% operating margin.